Objective: To inform guidelines concerning when to initiate combination antiretroviral therapy (ART), we investigated whether CD4 þ T-cell counts (CD4 cell counts) continue to increase over long periods of time on ART. Losses-to-follow-up and some patients discontinuing ART at higher CD4 cell counts hamper such evaluation, but novel statistical methods can help address these issues. We estimated the long-term CD4 cell count trajectory accounting for losses-to-follow-up and treatment discontinuations.
Introduction
The optimal time to start antiretroviral therapy (ART) for patients infected with the HIV is not well established.
There is currently considerable debate about whether ART should be initiated at a higher CD4 cell count threshold than the 350 cells/ml advocated in recent guidelines [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . Because mortality and morbidity rates are low at higher CD4 cell counts, a randomized trial to address this question would require a large sample size and long follow-up [5, [12] [13] [14] . CD4 cell counts are highly predictive of the short-term risk of HIV-related morbidity and mortality [15] [16] [17] [18] and so there is considerable interest in evaluating long-term effects of ART on CD4 cell count. One major question is whether treatment can be deferred without irreversible immune system damage [19] [20] [21] [22] , as might be suggested if CD4 cell counts normalize irrespective of the pretreatment CD4 cell count. A second major question is whether the beneficial effects of ART in raising CD4 cell counts are maintained long-term or are time limited and CD4 cell counts eventually stabilize or decline in patients on ART.
There are conflicting reports about the pattern of CD4 cell counts after multiple years of ART. Studies [23] [24] [25] [26] [27] of North American and European adults have variously concluded that CD4 cell counts continue to rise after 4-7 or more years of treatment or that the CD4 cell count stabilizes, overall [28, 29] or in a subset of patients [27, 30, 31] . Most analyses have restricted CD4 cell count assessment to times when plasma HIV-1 RNA (vRNA) was suppressed, for example, to less than 50 copies/ml. The characteristics of patients who remain virologically suppressed are likely different from those who do not, leading to possible selection biases. Hence, it is important to evaluate CD4 trajectories in complete populations initiating ART. Further biases may arise if dropout, often common, is ignored. For example, if more immunocompromised patients with lower CD4 cell counts drop out more frequently, an analysis that simply includes the patients in follow-up will overestimate the CD4 cell count trajectory in the entire population. Such issues may explain why different studies reach different conclusions regarding long-term CD4 cell count trajectories.
We evaluated the long-term CD4 cell count trajectory among patients who first initiated ART while participating in AIDS Clinical Trials Group (ACTG) study 384, a randomized clinical trial, which showed that efavirenz (EFV)-lamivudine (3TC)/zidovudine (ZDV) was a potent combination and helped to establish EFV-based regimens as initial treatment for HIV-infected patients [8, 32, 33] . Differences between the randomized arms were seen in vRNA suppression, but not in CD4 cell count increases over 3 years [32] [33] [34] . EFV-3TC/ZDV was the best initial regimen, having the lowest rate of protocol-defined virologic failure among the three-drug regimens; the four-drug regimens studied did not show benefit over this regimen [32, 33] .
We assessed three objectives regarding long-term CD4 cell count increases during ART, using data from ACTG 384 and subsequent follow-up in an observational study, ACTG A5001/AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) [35] . First, we evaluated the long-term CD4 cell count trajectory for the patients enrolled in ACTG 384 based on the treatment practices during the past few years, addressing the question 'What would have happened to the CD4 cell count trajectory in this cohort had all patients been followed for 7 years'? During follow-up, however, treatment guidelines changed, notably following the finding that discontinuation of ART at higher CD4 cell counts leads to increased morbidity [36] . Therefore, we also addressed the question 'What would have happened to the CD4 cell count trajectory of these patients had all remained on ART throughout the 7 years'? Last, we addressed the question 'What was the CD4 cell count trajectory among patients who remained in followup and were virologically suppressed for 7 years'? This focuses on a select subgroup of patients for whom treatment was successful over a long period, providing insight into results for the first two questions and an opportunity to compare our results with those of studies focusing on this subgroup. We also evaluate the long-term differences in CD4 cell count according to initial regimen in ACTG 384, and according to pretreatment CD4 cell count categories, because such differences inform the ongoing debate over the optimal CD4 cell count threshold at which ART should be initiated.
Methods

ACTG 384
ACTG 384 [32, 33] enrolled 898 patients in 1998-1999 at 58 sites in the United States. We excluded 82 participants enrolled in Italy, as they were ineligible for long-term follow-up in ALLRT. ACTG 384 ended in 2002. ARTnaive patients were randomized to either EFV (a nonnucleoside reverse transcriptase inhibitor, NNRTI), nelfinavir (NFV, a protease inhibitor), or both EFV and NFV (NNRTI/protease inhibitor) (double-blind) and were further randomized to add two nucleoside reverse transcriptase inhibitors (NRTIs): either ZDV þ 3TC or didanosine/stavudine (open-label). There were no enrollment restrictions on CD4 cell count; vRNA had to be at least 500 copies/ml.
AIDS Clinical Trials Group Longitudinal Linked Randomized Trials
Following ACTG 384, most (575, 64%) patients enrolled in ALLRT [35] , a long-term observational study for patients enrolled in randomized treatment studies. ALLRT did not provide ART. At the time of analysis, all participants had potential follow-up of 7 years.
Evaluations in both studies continued regardless of changes in or discontinuation of ART, including CD4 cell count and vRNA measurements every 8 or 16 weeks.
Patients provided written informed consent for participation in ACTG 384 and ALLRT. All sites received institutional review board approval for both studies.
CD4 cell count measurements
We focused on annual CD4 cell counts, enabling us to develop a model and hence adjust for loss-to-follow-up in the corresponding 1-year periods. Because ALLRT followed participants every 16 weeks, a patient's annual CD4 cell count was defined as the mean of up to three 16-week values closest to the actual year since start of ART. Baseline CD4 cell count was the mean of the two pretreatment CD4 cell counts in ACTG 384.
Virological suppression
Virological suppression was defined as no confirmed vRNA above 400 copies/ml, based on measurements every 16 weeks.
End of follow-up
End of follow-up was defined as the year of death or, if not known to be deceased, the last year a CD4 cell count was available.
Statistical analyses
We estimated the CD4 cell count trajectory, as represented by the median CD4 cell count for the 898 patients originally enrolled in the 7 successive years since starting ART, for each of the three scenarios described in the 'Introduction' section. For the analysis had everyone remained on treatment, we censored patients if they discontinued ART for more than 60 days. In estimating the median CD4 cell count, if a patient died, we ranked the patient lower than any surviving patient; this avoids the selection biases arising if the CD4 cell count trajectory is only evaluated among surviving patients. The median CD4 cell count then has the interpretation that 50% of the original population is alive with a CD4 cell count above that median.
To address informative censoring due to selective followup, that is, individuals with certain characteristics may be more likely to remain in follow-up (or on ART), we used inverse probability of censoring weighting (IPCW) [37, 38] . To illustrate the concept behind IPCW, suppose that a study population includes a subset of 10 identical patients of whom five are lost to follow-up. IPCW then assigns the five with observed data double the weight in the analysis. In general, IPCW assigns weights to patients on follow-up: the inverse of their estimated probability of being on follow-up based on their patient characteristics. This approach has been proven to lead to estimators with desirable statistical properties [37] . This analytical approach estimates outcomes in the entire study population, in contrast to describing a subgroup selected over time. In practice, the (unobserved) outcomes of patients who were lost-to-follow-up are represented by increasing the weight given to the outcomes of 'similar' patients who remained in follow-up. The weights are obtained from a logistic regression model used to describe the probability of remaining in follow-up at a given time in terms of covariate values observed in the past (so these covariates are the basis for identifying 'similar' patients).
The main assumption behind this method is that there are no (possibly unmeasured) factors that both affect the subsequent CD4 cell count trajectory and independently predict the probability of remaining in follow-up, which are not included in the logistic regression model. The logistic regression model used to estimate the weights, by estimating the probabilities of remaining in follow-up, used separate models during ACTG 384, the transition from ACTG 384 to ALLRT, and during ALLRT, as factors influencing follow-up might differ across these three situations. The covariates included were those that we considered might be confounding variables [38] , that is, predict loss to follow-up and also long-term CD4 cell count outcome: initial treatment, pre-ART CD4 cell count and log 10 vRNA, age, sex, race/ethnicity (white non-Hispanic/other), injection drug use (ever/ never), and time-varying variables, that is, recent CD4 cell count, change in CD4 cell count over the previous year, vRNA (<400 versus 400 copies/ml), and year since starting ART. In sensitivity analyses, we repeated the IPCW analysis using a single censoring model and a reduced single model obtained from stepwise variable selection; results (not shown) changed minimally. Standard errors were obtained by bootstrap [37] . For comparison, we also present results from a nonweighted (naive) analysis, which could be biased, for reasons discussed above. SAS 9.1.3 (SAS Institute Inc., Cary, North Carolina, USA) was used for all analyses.
Results
Selected baseline (pre-ART) characteristics of the 898 ACTG 384 patients enrolled in the United States are 82% men; 9% ever used intravenous drugs; 42% white nonHispanic; median age 36 years [interquartile range (IQR) 30-43 years]; median vRNA (log 10 copies/ml) 4.95 (IQR 4.33-5.53); CD4 cell count (cells/ml) of more than 500 (17%), 351-500 (20%), 201-350 (24%), and 200 or less (39%). These baseline characteristics did not differ significantly between baseline CD4 cell count categories except that there was a significant trend for higher vRNA with lower CD4 cell counts. During follow-up in ACTG 384, 18 (2.0%) patients died and 683 (76%) patients contributed CD4 cell data until the end of that study; 575 (64% of 898) continued observational follow-up in ALLRT, of whom 14 (2.4% of 575) died during ALLRT follow-up; and 356 (62% of 575) patients contributed CD4 cell data through 7 years after starting ART. This resulted in 543 patients (60%) who were in follow-up in year 4 or had died previously, and 388 (43%) in year 7. For the analysis had everyone remained on treatment, 430 patients (48%) were in follow-up and on ARTwithout any interruptions of more than 60 days in year 4, and 244 (27%) in year 7.
We found that older age, white non-Hispanic racial/ ethnicity group, female sex, noninjection drug user, higher pretreatment viral load, lower current CD4 cell count, higher CD4 cell count increase in the last year, and vRNA less than 400 copies/ml were significantly associated with increased probability of staying in follow-up in at least one of the models for retention. Initial treatment and year of follow-up were also significant. Figure 1 shows the nonweighted and IPCW-estimated intent-to-treat (i.e. ignoring ART discontinuations) median CD4 cell count over time, for patients initially on the standard of care regimen EFV-3TC/ZDV versus the other three-drug regimens versus the four-drug regimens. These IPCW-estimated medians show the CD4 cell count trajectory over time in the study population given the treatment practices between 1998 and 2007, had all patients actually remained in follow-up for 7 years (or until death). Although weights ranged from 1.02 to 15, there were only small differences between results from the nonweighted and IPCW analyses. Thus, although there were strong predictors of loss to follow-up, these did not markedly confound the evaluation of the long-term CD4 cell count trajectory. There was no significant difference in long-term median CD4 cell count trajectory between patients initially assigned to EFV-3TC/ZDV versus other initial regimens. In the overall study population, combining across initial treatments, the median CD4 cell count increased from 270 cells/ml prior to starting treatment to 433, 518, and 556 cells/ml at 1, 2, and 3 years and changed minimally thereafter to a median of 532 cells/ml at 7 years. Table 1 also shows the estimated 25th and 75th percentiles for CD4 cell counts in the study population at 3 and 7 years. These also changed very little after 3 years, indicating stability in CD4 cell counts between 3 and 7 years in the study population. Figure 2(a) shows the nonweighted and IPCW-estimated median CD4 cell counts over time by pretreatment CD4 cell category, showing again only small differences between the two analyses. The absolute changes in median CD4 cell count were similar for 3 years irrespective of pretreatment CD4 cell count category; thereafter, the trajectories differed, with an increase in the median CD4 cell count (from 369 to 453 cells/ml) for patients with pretreatment CD4 cell count of 200 cells/ml or less, and declines for patients in the pretreatment CD4 cell count categories of 201-350, 351-500, and more than 500 cells/ml ( Table 1) . The IPCW-estimated proportion of patients with a CD4 cell count of 350 cells/ml or less at (or dying before) 7 years, by pretreatment CD4 count category, was 33% for pretreatment CD4 cell count of 200 cells/ml or less, 24% for CD4 cell count of 201-350 cells/ml, 16% for CD4 cell count of 351-500 cells/ml, and 8% for CD4 cell count of more than 500 cells/ml (overall 23%). Table 1 also includes these percentages for thresholds of 200 and 500 cells/ml. Some patients discontinued ART for more than 60 days, and the proportion discontinuing increased with higher pretreatment CD4 cell counts, possibly explaining the decline in median CD4 cell counts in the intent-to-treat analysis for patients in the higher pretreatment CD4 cell count categories. This is addressed in the 'on-treatment' analysis, in which it is assumed that patients who discontinued ART might have remained on ART had they known of the potential adverse consequences of discontinuing ART identified in the Strategies for Management of Antiretroviral Therapy (SMART) study [36] . In the models for the on-treatment analysis, older age and vRNA below 400 copies/ml, but not CD4 cell count, significantly increased the probability of staying on treatment, given a patient remained in follow-up. Figure 2(b) shows the nonweighted and IPCW-estimated median CD4 cell counts over time, had all patients remained on ART throughout the 7 years without interruptions longer than 60 days. As for the intent-totreat analysis, the differences between results from the two analyses were generally small except for the highest pretreatment CD4 category (>500 cells/ml), for which the difference increased after year 4. In all categories of pretreatment CD4 cell count, the median CD4 cell count either stabilized or continued to rise for 7 years, although more slowly after the first 3 years of ART. Table 2 gives the estimated medians and 25th and 75th percentiles of the distribution of CD4 cell counts during years 3 and 7, had patients remained on ART. As with the intent-totreat analysis, there were minimal differences in median CD4 cell count according to type of initial ART. The medians and 25th and 75th percentiles typically showed modest increases between years 3 and 7, suggesting a general upward shift in the distribution of CD4 cell counts in the study population, both overall and by pretreatment CD4 cell count category. Had all patients remained on ART, the IPCW-estimated proportion of patients with a CD4 cell count below 350 cells/ml at (or dying before) 7 years after starting ART was 25% for pretreatment CD4 cell count of 200 cells/ml or less, 9% for CD4 cell count of 201-350 cells/ml, 3% for CD4 cell count of 351-500 cells/ml, and 2% for CD4 cell count of more than 500 cells/ml (overall 14%). Table 2 also includes these percentages for thresholds of 200 and 500 cells/ml. Figure 3 shows the median CD4 cell counts over time in the patients who were followed for 7 years by pretreatment CD4 cell count category, comparing those who did versus did not maintain virologic suppression throughout. In those patients who remained virologically suppressed for 7 years, the median CD4 cell count continued to rise over 7 years in the lower pretreatment CD4 cell count categories, and stabilized in the higher ones. The median CD4 cell count declined in later years among patients who were not virologically suppressed throughout 7 years.
Discussion
Our study found substantial improvements in median CD4 cell count during 7 years after HIV-infected patients first started ART in the randomized clinical trial ACTG 384, which established the combination of EFV-3TC/ZDV as a standard of care for initial treatment of HIV infection. The largest increases occurred during the first 1-2 years of follow-up and, in the study population as a whole, showed little change between 3 and 7 years. When changes in median CD4 cell count were evaluated by pretreatment CD4 cell count, patients in the lowest category considered, 200 cells/ml or less, experienced a modest gain between 3 and 7 years, whereas patients in the highest category, more than 500 cells/ml, experienced a decline.
However, some patients discontinued ART during follow-up, particularly those with higher pretreatment CD4 cell counts, a practice that is no longer recommended because of the SMART study [36] results. We, therefore, conducted a novel statistical analysis, IPCW, which estimated CD4 cell count trajectories, had all patients remained on ART. This showed that the median CD4 cell count continued to show a modest increase between 3 and 7 years after starting ART, both in the overall study population and across pretreatment CD4 cell count categories. Of note, this pattern was also seen when considering the 25th and 75th percentiles of the distribution of CD4 cell counts, indicating ongoing peripheral CD4 cell count reconstitution with continued ART in the broad population of patients.
Long-term CD4 cell count increases during ART Lok et al. 1871 Table 1 . Estimated CD4 R T-cell count outcomes (cells/ml) had all patients been followed for 7 years. Patients who began ART at lower CD4 cell counts continued to have lower CD4 cell counts than those who began ART at higher CD4 cell counts. We found this not only in the subset of patients for whom virologic suppression was maintained throughout the 7 years of follow-up, as found in other studies [25] [26] [27] 29, 31] , but also in our analyses, which evaluated the entire study population who started ART. We estimated that 33% of patients who originally started ARTwhen their CD4 cell counts were 200 cells/ml or less would have had CD4 cell counts 350 cells/ml or less at (or died before) 7 years in the intent-to-treat analysis; the IPCW model suggested that had all patients remained on ART for 7 years, 25% would still have CD4 cell counts below 350 cells/ml after 7 years. In contrast, among patients with pretreatment CD4 cell counts in the 351-500 and more than 500 cells/ml ranges, the latter estimates were 3 and 2%, respectively.
Thus, initiation of ART at higher CD4 cell counts than typically recommended in recent treatment guidelines appears to be associated with maintenance of CD4 cell counts at levels above 350 cells/ml (when the risk of HIVassociated morbidity and mortality is low) for almost all patients for at least 7 years. Postponing ART until the CD4 cell count drops below 350 cells/ml might be too conservative, as patients who are in the pretreatment CD4 cell count category of 201-350 cells/ml have a median 7-year CD4 cell count similar to patients with pretreatment CD4 cell count of 200 cells/ml or less.
In the subgroup of patients who maintained vRNA below 400 copies/ml for 7 years, we observed ongoing improvements in median CD4 cell counts among patients who started ART at CD4 cell counts less than 350 cells/ ml. Although this is a selected subgroup, this finding and similar findings in other studies [25, 29, 31] provide support for treatment management practices that promote sustained virologic suppression. Additionally, individuals without sustained virologic suppression are at risk for acquiring drug resistance mutations. However, it is difficult to distinguish between virologic failure due to drug resistance and virologic failure due to nonadherence or toxicity/intolerance, as it is often due to a combination of these factors.
We found no long-term differences in CD4 cell counts achieved according to initial category of randomized treatment between EFV-3TC/ZDVand the other three and four-drug regimens, a finding made possible by the ALLRT study wherein participants are followed longterm after their participation in randomized ACTG clinical trials and through changes in ARTregimens. Like ACTG 384, two other studies [39, 40] found no difference between randomized initial ART in shortterm CD4 cell count increases (2-3 years). The lack of long-term differences found in our study likely reflects the availability of multiple potent antiretroviral regimens, so that even after 7 years, most patients still have treatment options. In addition, of the six regimens studied in ACTG 384, only the EFV-3TC/ZDV regimen has remained a preferred regimen, and most patients discontinued use of the other regimens; of those randomized to EFV-3TC/ZDVand alive and in followup after 7 years, 54% were on their initial regimen as compared with 11% for the other three-drug regimens and 4% for the four-drug regimens.
A notable strength of our study is the well characterized patient population and the standardized prospective collection of data. The main limitation is that some patients in ACTG 384 did not enroll in the ALLRT study and some patients were lost to follow-up. In addition, some patients discontinued treatment during follow-up, particularly at higher CD4 cell counts, consistent with treatment management practices during the study period. We attempted to address these limitations by using the IPCW method. This method adjusts for factors that are included in the model used to derive weights related to the probability of remaining in follow-up (or on ART), which might also affect a patient's future CD4 cell count trajectory. It is possible, however, that there are other (unmeasured) factors that influenced patient decisions to stay in follow-up or stay on ART that might also have been associated with CD4 cell count outcome. Omitting such factors may lead to bias in our results. For example, among patients with similar covariate histories, if patients who discontinued ART would have had lower CD4 cell counts, had they continued on ART than patients who did actually continue on ART, then the IPCW method might overestimate the subsequent CD4 trajectory that could be achieved in the whole population, had everyone stayed on ART.
This study has other limitations. First, recommended ART regimens have changed during recent years, so CD4
Long-term CD4 cell count increases during ART Lok et al. 1873 Table 2 . Estimated CD4 R T-cell count outcomes (cells/ml) had all patients remained on antiretroviral therapy throughout the 7 years of follow-up. cell count outcomes might be different for patients who are starting ART now. As current regimens tend to be better tolerated and possibly more efficacious, in part because of simpler dosing (e.g. once daily) leading to improved adherence, patients starting ART now might have better CD4 cell count outcomes than in our study. Second, we studied a group of patients who enrolled in a clinical trial, most of whom subsequently participated in a long-term observational study. Outcomes might be different in a more general patient population, although the demographic characteristics of our patients were quite diverse. Third, it is possible that the better outcomes among patients starting ART at higher CD4 cell counts are attributable to differences in other patient characteristics. For example, it is possible that starting ART at higher CD4 cell counts is associated with health-seeking behavior, so patients starting ART at higher CD4 cell counts might be expected to fare better for this reason.
In summary, our study suggests that the median CD4 cell count in this population of patients who initiated NNRTI and protease inhibitor-based regimens increased for 3 years and then stabilized through 7 years of follow-up. However, when adjustment was made for discontinuation of ART, the median CD4 cell count continued to rise in later years. This trend was seen across all categories of pretreatment CD4 cell counts. However, even after 7 years, a significant proportion of patients who initiated ART with CD4 cell counts below 200 cells/ml still had counts below 350 cells/ml. The inability to normalize CD4 cell counts among many patients starting ART at low CD4 cell counts, even after 7 years of treatment, provides additional support to consider initiation of therapy at higher CD4 cell counts, consistent with recent observational studies that suggested benefits in terms of HIV-related morbidity and mortality [9, 41, 42] and the newly updated treatment guidelines [2] .
